Vision is to establish a leading ADC developer to treat high unmet need diseases such as cancer. Founded by the team that founded and sold Emergence T...
NMD Pharma A/S, a clinical-stage biotech company dedicated to developing novel and improved treatments for patients living with neuromuscular diseases, a...
The test uses highly sensitive PCR technology, requiring only a single nasal-swab sample to provide rapid, accurate qualitative detection and different...
The CE-IVD marked QIAstat-Dx Respiratory SARS-CoV-2 Panel is available in Malaysia expanded to 23 pathogens, now includes Chlamydophila pneumoniae&nb...
Detailed data from Phase 3 ECHELON-3 study demonstrate investigational ADCETRIS regimen reduced risk of death by 37 percent compared to chemotherapy ...
Thermo Fisher Scientific, a global leader in scientific research solutions, has introduced cutting-edge solutions aimed at enhancing research wor...
Recommendation for adults with uncontrolled COPD with raised blood eosinophils based on data from two landmark Phase 3 trials demonstrating Dupixent sign...
Bristol Myers Squibb announced that the European Commission (EC) has approved Opdivo®(nivolumab) in combination with cisplatin and gemcitabine ...
TROPION-Lung01 Phase III trial had a local progressive or metastatic non-small cell lung cancer with at least one treatment history in the past ( Datopot...
Efficacy and safety of AFM24 in combination with atezolizumab, a checkpoint inhibitor, is being evaluated in non-small cell lung cancer patients with E...
Helsinn Group (“Helsinn”), a global pharmaceutical company with a track record of over forty-five years of commercial execution and a strong ...
Eisai Co., Ltd. (CEO: Haruo Naito) and Biogen Inc. (CEO: Christopher A. Viehbacher) announced that the Ministry of Food and Drug Safety (MFDS) in South K...
The ALIGN study, focusing on atrasentan, an investigational oral selective endothelin A (ETA) receptor antagonist, revealed a remarkable 36.1% redu...
Transaction to include felzartamab, a potential first-in-class therapeutic candidate with promise as a pipeline-in-a-product across a range of immune-m...
© 2025 Biopharma Boardroom. All Rights Reserved.
